ATE362991T1 - Kondensierte plasmid-liposome komplex zur transfektion - Google Patents

Kondensierte plasmid-liposome komplex zur transfektion

Info

Publication number
ATE362991T1
ATE362991T1 AT98949342T AT98949342T ATE362991T1 AT E362991 T1 ATE362991 T1 AT E362991T1 AT 98949342 T AT98949342 T AT 98949342T AT 98949342 T AT98949342 T AT 98949342T AT E362991 T1 ATE362991 T1 AT E362991T1
Authority
AT
Austria
Prior art keywords
transfection
plasmid
liposome complex
selecting
condensed plasmid
Prior art date
Application number
AT98949342T
Other languages
English (en)
Inventor
Shi Huang
Edwin Oto
Mohammad Hassanipour
Bei Jin
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ATE362991T1 publication Critical patent/ATE362991T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/552Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
AT98949342T 1997-03-28 1998-09-11 Kondensierte plasmid-liposome komplex zur transfektion ATE362991T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/827,236 US5851818A (en) 1996-05-31 1997-03-28 Condensed plasmid-liposome complex for transfection
PCT/US1998/019067 WO2000015825A1 (en) 1997-03-28 1998-09-11 Condensed plasmid-liposome complex for transfection

Publications (1)

Publication Number Publication Date
ATE362991T1 true ATE362991T1 (de) 2007-06-15

Family

ID=26794355

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98949342T ATE362991T1 (de) 1997-03-28 1998-09-11 Kondensierte plasmid-liposome komplex zur transfektion

Country Status (10)

Country Link
US (1) US5851818A (de)
EP (1) EP1109926B1 (de)
JP (1) JP2002525270A (de)
AT (1) ATE362991T1 (de)
AU (1) AU9568698A (de)
CA (1) CA2342292A1 (de)
DE (1) DE69837819T2 (de)
ES (1) ES2286857T3 (de)
HK (1) HK1039633A1 (de)
WO (1) WO2000015825A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326356B1 (en) * 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US6133026A (en) * 1996-05-31 2000-10-17 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection
US5851818A (en) * 1996-05-31 1998-12-22 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection
US6071533A (en) 1996-11-12 2000-06-06 The Regents Of The University Of California Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
US6749863B1 (en) * 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
ATE511543T1 (de) * 1999-02-22 2011-06-15 Univ Georgetown Immunoliposome mit einem targeting- antikörperfragment zur systemischen genverabreichung
US7112337B2 (en) * 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
JP2003509060A (ja) * 1999-09-17 2003-03-11 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ 逆トランスフェクション方法
US20020006664A1 (en) * 1999-09-17 2002-01-17 Sabatini David M. Arrayed transfection method and uses related thereto
US20040197390A1 (en) * 2001-05-29 2004-10-07 Shi-Kun Huang Neutral-cationic lipid for systemic delivery of factor VIII gene
US8143195B2 (en) * 2000-01-24 2012-03-27 Yingjian Wang Arrays for bringing two or more reagents in contact with one or more biological targets and methods for making and using the arrays
US7429466B2 (en) * 2000-01-24 2008-09-30 Hypromatrix, Inc Methods and arrays for detecting biological molecules
WO2003000291A1 (en) * 2001-06-22 2003-01-03 Techno Network Shikoku Co., Ltd. Lipid vesicles, process for producing lipid vesicles and method of immobilizing gene on lipid vesicles
US6670129B2 (en) 2001-09-24 2003-12-30 Corning Incorporated Cell transfection apparatus and methods for making and using the cell transfection apparatus
EP3100719A3 (de) * 2002-05-15 2017-02-22 California Pacific Medical Center Zuführung von nukleinsäureähnlichen verbindungen
AU2003259827B2 (en) 2002-08-12 2008-09-04 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
EP1613285A2 (de) 2003-03-31 2006-01-11 Alza Corporation Fettpartikel mit asymmetrischer lipid-beschichtung und herstellungsverfahren dafür
EP1691780A2 (de) * 2003-11-21 2006-08-23 Alza Corporation Durch liposom-dna-komplex vermittelte genzufuhr mit spaltbarer peg-oberflächenmodifikation
US20060211004A1 (en) 2005-02-15 2006-09-21 Ilsley Diane D Methods and compositions for determining non-specific cytotoxicity of a transfection agent
JP4919397B2 (ja) * 2006-06-30 2012-04-18 北海道システム・サイエンス株式会社 核酸導入用組成物
JP4510842B2 (ja) * 2007-03-26 2010-07-28 キヤノン株式会社 ポリヒドロキシアルカノエート被覆リポソーム
AU2014233428B2 (en) 2013-03-15 2019-09-19 Loma Linda University Treatment of autoimmune diseases
RU2589280C1 (ru) * 2015-02-09 2016-07-10 Государственное автономное научное учреждение Республики Башкортостан "Центр аграрных исследований" Средство с липосомами, содержащими глутаминовую кислоту и экстракт прополиса, обладающее ноотропной активностью
CN109288794B (zh) * 2018-11-19 2021-02-23 上海交通大学 一种蜂毒素脂质体纳米制剂及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187260A (en) * 1988-09-06 1993-02-16 Sharifa Karali Process for the preparation of a high purity protamine-DNA complex and process for use of same
US5614503A (en) * 1993-11-12 1997-03-25 Aronex Pharmaceuticals, Inc. Amphipathic nucleic acid transporter
US5851818A (en) * 1996-05-31 1998-12-22 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection

Also Published As

Publication number Publication date
AU9568698A (en) 2000-04-03
ES2286857T3 (es) 2007-12-01
EP1109926A1 (de) 2001-06-27
US5851818A (en) 1998-12-22
DE69837819D1 (de) 2007-07-05
JP2002525270A (ja) 2002-08-13
DE69837819T2 (de) 2008-01-31
CA2342292A1 (en) 2000-03-23
WO2000015825A1 (en) 2000-03-23
HK1039633A1 (en) 2002-05-03
EP1109926B1 (de) 2007-05-23

Similar Documents

Publication Publication Date Title
DE69837819D1 (de) Kondensierte plasmid-liposome komplex zur transfektion
ATE209902T1 (de) Neue liposomkomplexe mit erhöhter systemischer verabreichung
DE69906977D1 (de) In liposomen verkapselte nukleinsäurekomplexe
WO1998019709A3 (en) Cationic reagents for transfection
EP0759694A4 (de) Verfahren zur in-vivo abgabe therapeutischer agenzien mittels liposomen
ATE322255T1 (de) Polyamid-oligomere
AU4711296A (en) Method for loading lipid vesicles
DE69730218D1 (de) Fusogene liposomen
WO1997030024A3 (de) Lipidverbindungen und deren verwendung z.b. in liposomen
NZ513829A (en) Encapsulation of bioactive complexes in liposomes
DK0734252T3 (da) Vincaalkaloidvesikler med forøget effektivitet og tumormålsøgningsegenskaber
WO2001049266A3 (en) Iron chelator delivery system
ES2185418T3 (es) Agentes previstos para tratar tumores, basados en liposomas y que contienen tamoxifeno.
EP1231895A4 (de) Modulares zielgerichtetes liposomales verabreichungssytem
WO2000045845A3 (en) Liposome composition and method for administration of a radiosensitizer
WO2001078785A3 (de) Wirkstoff-konjugate mit intrazellulär wirksamen liganden
WO1999064439A3 (en) Methods for increasing cationic antimicrobial peptides
BR9811579B1 (pt) ácidos 3-ciano-2,4-dialógeno-5-fluorobenzóicos e processo para a preparação dos mesmos.
EA200100269A1 (ru) Иммуногенные липосомные композиции
DE3851842D1 (de) Wässrige bereitung von liposomenzusammensetzungen.
DE69520231D1 (de) Liposomzubereitungen enthaltend hybrid-interferon
WO2000074646A3 (de) Neue liposomale vektorkomplexe und deren verwendung für die gentherapie
US20030003584A1 (en) Liposomal vector binding protein for hepatocyte DNA delivery
UA25289C2 (uk) Спосіб приготування горілки "імператорська"

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties